News

CalciMedica Announces that FDA Has Strongly Recommended Moving to a Blinded Placebo-controlled Trial with Auxora™ in Patients with Severe COVID-19 Pneumonia

May 21, 2020

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Announces Independent Safety Review Committee Recommendation to Continue Phase 2 Study of CM4620-IE in Patients with Severe COVID-19 Pneumonia on Low-Flow Oxygen Therapy

May 7, 2020

LA JOLLA, Calif., May 7, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment …

CalciMedica Expands Clinical Study to Assess CM4620-IE in Patients with Critical COVID-19 Pneumonia on High-Flow Oxygen Therapy

April 30, 2020

Phase 2 open-label study expands to additional sites across the U.S. and aims to enroll 120 patients LA JOLLA, Calif., April 30, 2020 – CalciMedica Inc. …

FDA Grants CalciMedica Permission to Begin Dosing CM4620-IE in Patients with Severe COVID-19 Pneumonia under a Newly Opened IND

April 9, 2020

Regions Hospital in St. Paul, Minnesota has begun a Phase 2 clinical study of CM4620-IE in patients with severe COVID-19 pneumonia this week, and Henry …

CalciMedica to Present Results of PD/PK Study in Acute Pancreatitis Patients for Its CRAC Channel Inhibitor CM4620 at APA Annual Meeting

November 7, 2019

LA JOLLA, CA, November 7, 2019 /PRNewswire/ — Kenneth Stauderman, Ph.D., CalciMedica’s Chief Scientific Officer, is presenting a poster at the American Pancreas Association annual …